{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:10:53Z","timestamp":1791407453944,"version":"4.3.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s11894-005-0016-y","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T18:37:27Z","timestamp":1179599847000},"page":"249-256","source":"Crossref","is-referenced-by-count":28,"title":["Diagnosis and treatment of irritable bowel syndrome: State of the art"],"prefix":"10.1007","volume":"7","author":[{"given":"Kirsten","family":"Tillisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/gast.2002.37095b","volume":"123","author":"American Gastroenterology Association","year":"2002","unstructured":"American Gastroenterology Association: American Gastroenterological Association medical position statement: Irritable bowel syndrome. Gastroenterology 2002, 123:2105\u20132107. This position statement provides a comprehensive overview of the pathophysiology, diagnosis, and treatment of IBS.","journal-title":"Gastroenterology"},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2036.2003.t01-1-01736.x","volume":"18","author":"JM Inadomi","year":"2003","unstructured":"Inadomi JM, Fennerty MB, Bjorkman D: Systematic review: The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:671\u2013682.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"IM Gralnek","year":"2000","unstructured":"Gralnek IM, Hays RD, Kilbourne A, et al.: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119:654\u2013660.","journal-title":"Gastroenterology"},{"key":"16_CR4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1572-0241.2003.07296.x","volume":"98","author":"GF Longstreth","year":"2003","unstructured":"Longstreth GF, Wilson A, Knight K, et al.: Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003, 98:600\u2013607.","journal-title":"Am J Gastroenterol"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"i67","DOI":"10.1136\/gut.51.suppl_1.i67","volume":"51","author":"M Delvaux","year":"2002","unstructured":"Delvaux M: Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002, 51:i67-i71.","journal-title":"Gut"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0016-5085(97)70220-8","volume":"112","author":"DH Silverman","year":"1997","unstructured":"Silverman DH, Munakata JA, Ennes H, et al.: Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997, 112:64\u201372.","journal-title":"Gastroenterology"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1023\/A:1025455330704","volume":"48","author":"Y Ringel","year":"2003","unstructured":"Ringel Y, Drossman DA, Turkington TG, et al.: Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci 2003, 48:1774\u20131781.","journal-title":"Dig Dis Sci"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00006842-200105000-00006","volume":"63","author":"BD Naliboff","year":"2001","unstructured":"Naliboff BD, Derbyshire SW, Munakata J, et al.: Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001, 63:365\u2013375.","journal-title":"Psychosom Med"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.51.3.410","volume":"51","author":"KR Neal","year":"2002","unstructured":"Neal KR, Barker L, Spiller RC: Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410\u2013413.","journal-title":"Gut"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2003.09.028","volume":"125","author":"SP Dunlop","year":"2003","unstructured":"Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003, 125:1651\u20131659.","journal-title":"Gastroenterology"},{"key":"16_CR11","first-page":"II43","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45:II43-II47.","journal-title":"Gut"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/bmj.2.6138.653","volume":"2","author":"AP Manning","year":"1978","unstructured":"Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. BMJ 1978, 2:653\u2013654.","journal-title":"BMJ"},{"key":"16_CR13","first-page":"92","volume":"2","author":"WG Thompson","year":"1989","unstructured":"Thompson WG, Dotevall G, Drossman DA, et al.: Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989, 2:92\u201395.","journal-title":"Gastroenterol Int"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2004.03.012","volume":"126","author":"BM Spiegel","year":"2004","unstructured":"Spiegel BM, DeRosa VP, Gralnek IM, et al.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis. Gastroenterology 2004, 126:1721\u20131732.","journal-title":"Gastroenterology"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1572-0241.1999.01437.x","volume":"94","author":"SJ Vanner","year":"1999","unstructured":"Vanner SJ, Depew WT, Paterson WG, et al.: Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999, 94:2912\u20132917.","journal-title":"Am J Gastroenterol"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1572-0241.2005.41211.x","volume":"100","author":"K Tillisch","year":"2005","unstructured":"Tillisch K, Labus J, Naliboff B, et al.: Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005, 100:896\u2013904.","journal-title":"Am J Gastroenterol"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1053\/j.gastro.2004.12.006","volume":"128","author":"DA Drossman","year":"2005","unstructured":"Drossman DA, Morris CB, Hu Y, et al.: A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator. Gastroenterology 2005, 128:580\u2013589.","journal-title":"Gastroenterology"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2002.32392","volume":"122","author":"WE Whitehead","year":"2002","unstructured":"Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002, 122:1140\u20131156.","journal-title":"Gastroenterology"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/bmj.299.6708.1138","volume":"299","author":"DG Maxton","year":"1989","unstructured":"Maxton DG, Morris JA, Whorwell PJ: Ranking of symptoms by patients with the irritable bowel syndrome. BMJ 1989, 299:1138.","journal-title":"BMJ"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1111\/j.1572-0241.2001.05258.x","volume":"96","author":"RL Levy","year":"2001","unstructured":"Levy RL, Von Korff M, Whitehead WE, et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001, 96:3122\u20133129.","journal-title":"Am J Gastroenterol"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1001\/archinte.164.16.1773","volume":"164","author":"BM Spiegel","year":"2004","unstructured":"Spiegel BM, Gralnek IM, Bolus R, et al.: Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004, 164:1773\u20131780.","journal-title":"Arch Intern Med"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","volume":"109","author":"L Agreus","year":"1995","unstructured":"Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995, 109:671\u2013680.","journal-title":"Gastroenterology"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1111\/j.1572-0241.1999.01643.x","volume":"94","author":"AD Sperber","year":"1999","unstructured":"Sperber AD, Atzmon Y, Neumann L, et al.: Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999, 94:3541\u20133546.","journal-title":"Am J Gastroenterol"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00011","volume":"134","author":"LA Aaron","year":"2001","unstructured":"Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001, 134:868\u2013881.","journal-title":"Ann Intern Med"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0016-5085(88)80018-0","volume":"95","author":"WE Whitehead","year":"1988","unstructured":"Whitehead WE, Bosmajian L, Zonderman AB, et al.: Symptoms of psychological distress associated with irritable bowel syndrome. Gastroenterology 1988, 95:709\u2013714.","journal-title":"Gastroenterology"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-123-9-199511010-00008","volume":"123","author":"DA Drossman","year":"1995","unstructured":"Drossman DA: Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995, 123:688\u2013697.","journal-title":"Ann Intern Med"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","volume":"53","author":"W Atkinson","year":"2004","unstructured":"Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004, 53:1459\u20131464.","journal-title":"Gut"},{"key":"16_CR28","first-page":"S7","volume":"97","author":"LJ Brandt","year":"2002","unstructured":"Brandt LJ, Bjorkman D, Fennerty MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97:S7-S26. This review provides an evidence-based evaluation of IBS symptom criteria and treatment options with an extensive reference list of original sources.","journal-title":"Am J Gastroenterol"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","volume":"15","author":"T Poynard","year":"2001","unstructured":"Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355\u2013361.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365529709025060","volume":"32","author":"WM Sun","year":"1997","unstructured":"Sun WM, Read NW, Verlinden M: Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997, 32:34\u201338.","journal-title":"Scand J Gastroenterol"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.42.1.42","volume":"42","author":"CP Bearcroft","year":"1998","unstructured":"Bearcroft CP, Perrett D, Farthing MJG: Postprandial plasma 5-hydroxytryptamine in diarrhea predominant irritable bowel syndrome. Gut 1998, 42:42\u201344.","journal-title":"Gut"},{"key":"16_CR32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gut.52.5.663","volume":"52","author":"LA Houghton","year":"2003","unstructured":"Houghton LA, Atkinson W, Whitaker RP, et al.: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:663\u2013667.","journal-title":"Gut"},{"key":"16_CR33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/003655299750025110","volume":"34","author":"M El-Salhy","year":"1999","unstructured":"El-Salhy M, Norrgard O, Spinnell S: Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol 1999, 34:1007\u20131011.","journal-title":"Scand J Gastroenterol"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2004.03.013","volume":"126","author":"MD Coates","year":"2004","unstructured":"Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657\u20131664.","journal-title":"Gastroenterology"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","volume":"355","author":"M Camilleri","year":"2000","unstructured":"Camilleri M, Northcutt AR, Kong S, et al.: The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised, placebo controlled study. Lancet 2000, 355:1035\u20131040.","journal-title":"Lancet"},{"key":"16_CR36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","volume":"13","author":"M Camilleri","year":"1999","unstructured":"Camilleri M, Mayer E, Drossman D, et al.: Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149\u20131151.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","volume":"161","author":"M Camilleri","year":"2001","unstructured":"Camilleri M, Chey W, Mayer E, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med 2001, 161:1733\u20131740.","journal-title":"Arch Intern Med"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","volume":"14","author":"K Bardhan","year":"2000","unstructured":"Bardhan K, Bodemar G, Geldof H, et al.: A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000, 14:23\u201324.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","volume":"100","author":"L Chang","year":"2005","unstructured":"Chang L, Ameen VZ, Dukes GE, et al.: A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005, 100:115\u2013123.","journal-title":"Am J Gastroenterol"},{"key":"16_CR40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1053\/gast.2002.35990","volume":"123","author":"SM Berman","year":"2002","unstructured":"Berman SM, Chang L, Suyenobu B, et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002, 123:969\u2013977.","journal-title":"Gastroenterology"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"A42","DOI":"10.1053\/j.gastro.2003.10.043","volume":"126","author":"M Bradette","year":"2004","unstructured":"Bradette M, Moennikes H, Carter F, et al.: Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology 2004, 126:A42.","journal-title":"Gastroenterology"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"A643","DOI":"10.1053\/j.gastro.2003.11.057","volume":"126","author":"G Coremans","year":"2004","unstructured":"Coremans G, Clouse RE, Carter F, et al.: Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D). Gastroenterology 2004, 126:A643.","journal-title":"Gastroenterology"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","volume":"118","author":"CM Prather","year":"2000","unstructured":"Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 2000, 118:463\u2013468.","journal-title":"Gastroenterology"},{"issue":"10","key":"16_CR44","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","volume":"15","author":"SA Muller-Lissner","year":"2001","unstructured":"Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15(10):1655\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","volume":"52","author":"J Kellow","year":"2003","unstructured":"Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671\u2013676.","journal-title":"Gut"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1542-3565(04)00356-8","volume":"2","author":"JF Johanson","year":"2004","unstructured":"Johanson JF, Wald A, Tougas G, et al.: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004, 2:796\u2013805.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"16_CR47","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1046\/j.1365-2036.2002.01347.x","volume":"16","author":"G Tougas","year":"2002","unstructured":"Tougas G, Snape WJ Jr, Otten MH, et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002, 16:1701\u20131708.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5085(03)00669-3","volume":"125","author":"DA Drossman","year":"2003","unstructured":"Drossman DA, Toner BB, Whitehead WE, et al.: Cognitivebehavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19\u201331.","journal-title":"Gastroenterology"},{"key":"16_CR49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/gast.2003.50055","volume":"124","author":"F Creed","year":"2003","unstructured":"Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303\u2013317.","journal-title":"Gastroenterology"},{"key":"16_CR50","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","volume":"99","author":"G Tabas","year":"2004","unstructured":"Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: A double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914\u2013920.","journal-title":"Am J Gastroenterol"},{"key":"16_CR51","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1037\/0022-006X.72.6.1100","volume":"72","author":"JM Lackner","year":"2004","unstructured":"Lackner JM, Mesmer C, Morley S, et al.: Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004, 72:1100\u20131113.","journal-title":"J Consult Clin Psychol"},{"key":"16_CR52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/gut.52.11.1623","volume":"52","author":"WM Gonsalkorale","year":"2003","unstructured":"Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ: Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003, 52:1623\u20131629.","journal-title":"Gut"},{"key":"16_CR53","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503\u20133506.","journal-title":"Am J Gastroenterol"},{"key":"16_CR54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1572-0241.2003.07946.x","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412\u2013419.","journal-title":"Am J Gastroenterol"},{"key":"16_CR55","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1023\/A:1021039032413","volume":"47","author":"M Pimentel","year":"2002","unstructured":"Pimentel M, Soffer EE, Chow EJ, et al.: Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639\u20132643.","journal-title":"Dig Dis Sci"},{"key":"16_CR56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0016-5085(91)90459-X","volume":"101","author":"JM Hills","year":"1991","unstructured":"Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991, 101:55\u201365.","journal-title":"Gastroenterology"},{"key":"16_CR57","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.280.18.1585","volume":"280","author":"A Bensoussan","year":"1998","unstructured":"Bensoussan A, Talley NJ, Hing M, et al.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998, 280:1585\u20131589.","journal-title":"JAMA"},{"key":"16_CR58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2036.2004.01859.x","volume":"19","author":"A Madisch","year":"2004","unstructured":"Madisch A, Holtmann G, Plein K, Hotz J: Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004, 19:271\u2013279.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR59","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1572-0241.2004.30028.x","volume":"99","author":"RB Rohrbock","year":"2004","unstructured":"Rohrbock RB, Hammer J, Vogelsang H, et al.: Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol 2004, 99:1990\u20131997.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-005-0016-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0016-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:03:52Z","timestamp":1559419432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-005-0016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11894-005-0016-y","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}